# US 2026/0076940 A1 · Treatment regimen for the treatment of neurological diseases or conditions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0076940 A1
- Document ID: US20260076940A1
- Status: Published application
- Kind: A1
- Application number: 19/401,124
- Filed: 2025-11-25
- Published: 2026-03-19
- Earliest claimed: 2019-10-30
- Assignees: Accure Therapeutics, S.L.
- Applicants: Accure Therapeutics, S.L.
- Inventors: Pablo VILLOSLADA DIAZ
- Web page: https://patentgrep.com/patent/US20260076940A1

## CPC

- A61K 31/4015: having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
- A61K 31/18: Sulfonamides (compounds containing a para-N-benzene-sulfonyl-N- group A61K31/63)
- A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 27/02: Ophthalmic agents
- A61P 27/06: Antiglaucoma agents or miotics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

It relates to BN201 or a pharmaceutically acceptable salt thereof, for use in the treatment of acute optic neuritis that is efficacious for at least 28 days wherein the treatment is administered once a day for 5-7 days.

## Claims

### Claim 1

A method for the treatment of acute optic neuritis that is efficacious for at least 28 days, comprising administering an effective amount of a compound of the structure:
or a pharmaceutically acceptable salt thereof in a pharmaceutically acceptable composition;
wherein the treatment is administered once a day for 5-7 days.

### Claim 2 (depends on 1)

The method of claim 1, wherein the treatment is administered for 5 days.

### Claim 3 (depends on 1)

The method of claim 1, wherein the treatment is administered for 6 days.

### Claim 4 (depends on 1)

The method of claim 1, wherein the treatment is administered for 7 days.

### Claim 5 (depends on 1)

The method of claim 1, wherein the compound is administered intravenously.

### Claim 6 (depends on 1)

The method of claim 1, wherein the compound is administered intraperitoneally.
